A stats-rich infographic view of FDA market access, HIPAA data rules, reimbursement coding, and the commercialization gauntlet that shapes healthcare B2B sales.
FDA device classes: low, moderate, and high risk.
Common FDA pathway for many Class II medical devices.
PHI-touching vendors need security and privacy readiness.
Major commercialization gates before scalable adoption.
FDA regulates medical devices, drugs, and software-as-a-medical-device. Without proper clearance, selling legally becomes difficult.
HIPAA governs protected health information. Software touching patient data must address privacy, security, and business associate requirements.
CPT, DRG, and CMS reimbursement logic can determine whether providers can bill for a solution and justify purchase.
Innovation begins with prototype development and early funding.
FDA submission, clinical evidence, 510(k), or PMA pathways.
Securing CPT or DRG codes so providers can bill for the solution.
GPO contracts, IDN value analysis committees, and IT security reviews.
In healthcare B2B, you are not just selling features; you are selling compliance and reimbursement. If your team cannot speak FDA, HIPAA, and reimbursement language, gatekeepers can block the deal.
High intent for “SOC2 Type II” or “HITRUST” from a health system can signal an active vendor displacement cycle.
Do not wait until the end of the deal to address security.
Know the value analysis committee schedule and review criteria.
Make sure CPT, DRG, or billing pathways are active and understood.